<?xml version="1.0" encoding="UTF-8"?>
<record
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xsi:schemaLocation="http://www.loc.gov/MARC21/slim http://www.loc.gov/standards/marcxml/schema/MARC21slim.xsd"
    xmlns="http://www.loc.gov/MARC21/slim">

  <leader>05168nab a2200385 i 4500</leader>
  <controlfield tag="003">BR-BrBNA</controlfield>
  <controlfield tag="005">20240819121927.0</controlfield>
  <controlfield tag="008">240819b2016    bl.mr|pooa||| 00| 0 eng |</controlfield>
  <datafield tag="040" ind1=" " ind2=" ">
    <subfield code="a">BR-BrBNA</subfield>
    <subfield code="b">eng</subfield>
  </datafield>
  <datafield tag="072" ind1=" " ind2=" ">
    <subfield code="a">L73</subfield>
    <subfield code="b">5500</subfield>
  </datafield>
  <datafield tag="100" ind1=" " ind2=" ">
    <subfield code="a">Schroder, Deise Cristine </subfield>
  </datafield>
  <datafield tag="100" ind1=" " ind2=" ">
    <subfield code="a">Stocco, Matias Bassinello </subfield>
  </datafield>
  <datafield tag="100" ind1=" " ind2=" ">
    <subfield code="a">Isoton, Deborah de Arruda </subfield>
  </datafield>
  <datafield tag="100" ind1=" " ind2=" ">
    <subfield code="a">Silva, Carla Patricia Amarante e </subfield>
  </datafield>
  <datafield tag="100" ind1=" " ind2=" ">
    <subfield code="a">Braga, &#xCD;sis Assis </subfield>
  </datafield>
  <datafield tag="100" ind1=" " ind2=" ">
    <subfield code="a">Silva, &#xC9;rica Pereira da </subfield>
  </datafield>
  <datafield tag="100" ind1=" " ind2=" ">
    <subfield code="a">Maciel, Camila do Esp&#xED;rito Santo </subfield>
  </datafield>
  <datafield tag="100" ind1=" " ind2=" ">
    <subfield code="a">Maruyama, Fernanda Harumi </subfield>
  </datafield>
  <datafield tag="100" ind1=" " ind2=" ">
    <subfield code="a">Nakazato, Luciano </subfield>
  </datafield>
  <datafield tag="100" ind1=" " ind2=" ">
    <subfield code="a">Aguiar, Daniel Moura de </subfield>
  </datafield>
  <datafield tag="100" ind1=" " ind2=" ">
    <subfield code="a">Mendon&#xE7;a, Adriane Jorge</subfield>
  </datafield>
  <datafield tag="100" ind1=" " ind2=" ">
    <subfield code="a">Ribeiro, Alexandre Pinto </subfield>
  </datafield>
  <datafield tag="245" ind1=" " ind2=" ">
    <subfield code="a">Firocoxib on aqueous humor prostaglandin E2  levels for controlling experimentallyinduced breakdown of blood-aqueous barrier in healthy and Toxoplasma gondii-seropositive cats</subfield>
  </datafield>
  <datafield tag="500" ind1=" " ind2=" ">
    <subfield code="a">Publica&#xE7;&#xE3;o on-line; 23 ref.; Sumaries (En, Pt)</subfield>
  </datafield>
  <datafield tag="520" ind1=" " ind2=" ">
    <subfield code="a">

ABSTRACT - This study aimed to evaluate the effects of firocoxib for controlling experimentally-induced breakdown of the bloodaqueous barrier in healthy and Toxoplasma gondii-seropositive cats. Thirty two cats with no ocular abnormalities were used. Groups (n=8/each) were formed with healthy cats that received 5mg g-1 of oral firocoxib (FH) or no treatment (CH) on day 0; seropositive cats for anti-T. gondii specific immunoglobulin G (IgG) were grouped (n=8/each) and treated in a similar fashion (FT and CT). On day 1, cats of all groups received the same treatment protocol, and 1h later, aqueocentesis was performed under general anesthesia (M0). Following 1h, the same procedure was repeated (M1). Quantitation of aqueous humor total protein and prostaglandin E2  (PGE2 ) were determined. Aqueous samples of seropositive cats were tested for anti-T. gondii specific IgG. In M0, aqueous samples of CT showed a significantly higher concentration of PGE2  in comparison with other groups (P&lt;0.05). In all groups, PGE2  concentration increased significantly from M0 to M1 (P=0.001). PGE2  values did not change significantly between groups in M1 (P=0.17). Anti-T. gondii specific IgG were reported only in samples of M1, and aqueous titers did not change significantly between FT and CT (P=0.11). Although we have observed that aqueous humor PGE2  levels were significantly higher in cats of CT group during M0, such increase was not able to break the blood-aqueous barrier and cause anterior uveitis. Firocoxib did not prevent intraocular inflammation after aqueocentesis, in healthy and toxoplasmosis-seropositive cats.

Key words: aqueous humor, intraocular inflammation, NSADs, toxoplasmosis.</subfield>
  </datafield>
  <datafield tag="520" ind1=" " ind2=" ">
    <subfield code="a">

RESUMO - Objetivou-se avaliar a efic&#xE1;cia do firocoxib no controle da quebra da barreira hematoaquosa experimentalmente induzida em gatos saud&#xE1;veis e com sorologia positiva para toxoplasmose. Para tanto, utilizaram-se trinta e dois gatos sem altera&#xE7;&#xF5;es oculares, alocados em grupos (n=8/cada) compostos por gatos saud&#xE1;veis que receberam tratamento pr&#xE9;vio com 5mg g-1 de firocoxib oral (HF) ou sem nenhum tratamento (CH) no dia 0, e por gatos com sorologia positiva para toxoplasmose tratados de maneira similar (FT e CT). No dia 1, os gatos de todos os grupos receberam o mesmo protocolo de tratamento do dia anterior e, 1h depois, foram submetidos &#xE0; paracentese da c&#xE2;mara anterior sob anestesia geral (M0). Ap&#xF3;s 1h, realizou-se nova paracentese (M1). Mediante a colheita de humor aquoso (M0 e M1), quantificaramse os valores de prote&#xED;na total e prostaglandina E2  (PGE2) das amostras. As amostras dos gatos com sorologia positiva para toxoplasmose foram tamb&#xE9;m testadas para anticorpos anti-T. gondii IgG espec&#xED;ficos. Em M0, as amostras de humor aquoso de CT apresentaram concentra&#xE7;&#xE3;o de PGE2  significativamente superior aos demais grupos (P&lt;0,05). Em todos os grupos, a concentra&#xE7;&#xE3;o de PGE2 aumentou significativamente de M0 para M1 (P=0,001), no entanto, n&#xE3;o houve diferen&#xE7;a significativa entre os grupos em M1 (P=0,17). Anticorpos anti-T. gondii IgG espec&#xED;ficos foram encontrados somente em amostras de M1, e os t&#xED;tulos n&#xE3;o diferiram significativamente entre FT e CT (P=0,11). Valores de PGE2  significativamente superiores no CT durante M0 n&#xE3;o foram capazes de induzir a quebra da barreira hematoaquosa e causar uve&#xED;te anterior nos gatos deste estudo. O firocoxib, por sua vez, n&#xE3;o foi capaz de prevenir a quebra da barreira hematoaquosa ap&#xF3;s realiza&#xE7;&#xE3;o de paracente na c&#xE2;mara anterior em gatos saud&#xE1;veis e com sorologia positiva para toxoplasmose.

Palavras-chave: humor aquoso, inflama&#xE7;&#xE3;o intraocular, AINEs, toxoplasmose.</subfield>
  </datafield>
  <datafield tag="650" ind1=" " ind2=" ">
    <subfield code="a">GATO</subfield>
  </datafield>
  <datafield tag="650" ind1=" " ind2=" ">
    <subfield code="a">TOXOPLASMA</subfield>
  </datafield>
  <datafield tag="650" ind1=" " ind2=" ">
    <subfield code="a">DOEN&#xC7;A ANIMAL</subfield>
  </datafield>
  <datafield tag="650" ind1=" " ind2=" ">
    <subfield code="a">VETERIN&#xC1;RIA</subfield>
  </datafield>
  <datafield tag="773" ind1="0" ind2=" ">
    <subfield code="0">2408</subfield>
    <subfield code="9">314928</subfield>
    <subfield code="d">Santa Maria-RS Universidade Federal de Santa Maria - Centro de Ci&#xEA;ncias Rurais 1991</subfield>
    <subfield code="o">2024-1179</subfield>
    <subfield code="t">Ci&#xEA;ncia Rural (Brazil)</subfield>
    <subfield code="x">0103-8478</subfield>
    <subfield code="g">v. 46(6) p. 1053-1058; (2016)</subfield>
    <subfield code="w">BR2024001341</subfield>
  </datafield>
  <datafield tag="856" ind1=" " ind2=" ">
    <subfield code="u">https://www.scielo.br/j/cr/a/sDbFYqftN8CgRnYKQtxkjLk/?format=pdf&amp;lang=en</subfield>
  </datafield>
  <datafield tag="942" ind1=" " ind2=" ">
    <subfield code="c">Anal&#xED;tica</subfield>
  </datafield>
  <datafield tag="999" ind1=" " ind2=" ">
    <subfield code="c">300946</subfield>
    <subfield code="d">300946</subfield>
  </datafield>
</record>
